REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Mechanism of action (MOA).
REVLIMID works to enhance anti-myeloma activity.1,2*
Lenalidomide is an IMiD® compound that has immunomodulatory, tumoricidal, and antiangiogenic properties. Lenalidomide also has the ability to synergize with dexamethasone to augment anti-myeloma activity.*
*As shown in vitro and in vivo.
STIMULATES1
Exhibits immunomodulatory properties.
- Activates and increases number of T cells and NK cells
- Increases number of NKT cells
- Inhibits pro-inflammatory cytokines (e.g., TNF-a, and IL-6) by monocytes
STRIKES1
Inhibits cell proliferation and induces apoptosis of tumor cells in vitro and inhibition of tumor growth in vivo, leading to a decrease in tumor burden.
STARVES2
Inhibits angiogenesis by reducing levels of VEGF, TNF-a, and IL-6.
IL, interleukin; IMiD, immunomodulatory; NK, natural killer; NKT, natural killer T; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
References: 1. REVLIMID [package insert]. Summit, NJ: Celgene Corp; 2019. 2. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.